Drug Name: Sunlenca
Active Ingredient: lenacapavir
Indications: To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations
Approval Date: 12/22/2022
Company: Gilead Sciences, Inc
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215973s000lbl.pdf